Phreesia Stock Price, News & Analysis

Phreesia, Inc. (NYSE: PHR) announced it will release its fiscal Q1 2024 financial results on May 31, 2023, after market close. A press release and stakeholder letter will be available on the investor website. Following this, a conference call is scheduled for the same day at 5 PM ET to discuss the financial results. Phreesia is recognized for its patient activation solutions and enabled over 120 million patient visits in 2022, which represents over 10% of U.S. patient visits.

Unlimited Systems and Phreesia have announced a partnership to integrate their services, enhancing patient experience in oncology practices. This collaboration will allow independent oncology practices to utilize Phreesia's patient-driven intake tools, offering mobile check-in and automated appointment reminders. Notably, practices using Phreesia have reported that 69% of patients self-check-in, saving over 5 minutes per visit, and 86% have had insurance verified before appointments. The integration aims to reduce staff burdens and improve operational efficiencies through features like real-time insurance verification and streamlined workflows.

Phreesia, Inc. (NYSE: PHR) has appointed Balaji Gandhi as its new Chief Financial Officer, effective March 24, 2023. Gandhi, who has over 25 years of experience in healthcare services and technology, joined Phreesia in 2019 and has served as Senior Vice President of Investor Relations. He succeeds Randy Rasmussen, who will assist in the transition as a Strategic Advisor. CEO Chaim Indig emphasized Gandhi's deep understanding of the company and his successful communication with the investment community, aiming to drive long-term value for stakeholders.

Phreesia, Inc. (NYSE: PHR) reported fiscal fourth quarter and year results ending January 31, 2023, showcasing significant growth yet persistent net losses. Q4 revenue reached $76.6 million, a 32% increase YOY, with a total annual revenue of $280.9 million, also up 32%. The average number of healthcare services clients (AHSCs) grew 36% YOY to 3,140, though healthcare services revenue per AHSC fell 4%. A net loss of $38.0 million marks an improvement from $46.5 million last year. Despite cash reserves of $176.7 million, net losses expanded to $176.1 million for FY 2023. For FY 2024, Phreesia forecasts revenue between $353 million and $356 million.

Phreesia has announced that Alexandra Beneville, Vice President of Life Sciences Content Strategy, has been named to MM+M's 2023 'Women to Watch' class, recognizing her as one of 18 influential women in the healthcare marketing field. Since joining Phreesia in August, Beneville has significantly impacted the company's Life Sciences strategy and operations, driving growth and enhancing diversity and inclusion. Phreesia, listed on the NYSE under the symbol PHR, focuses on empowering life sciences companies through tailored patient interactions and insights.

Phreesia, Inc. (NYSE: PHR) will announce its fiscal fourth-quarter 2023 financial results on March 22, 2023, after market close. A press release detailing the results, along with a quarterly stakeholder letter, will be available on Phreesia's investor website. A conference call is scheduled for 5 PM ET the same day to discuss the results. Phreesia provides a comprehensive SaaS platform for healthcare organizations to improve patient intake processes, enhancing both patient experience and clinical efficiency.

Phreesia has collaborated with the Ad Council on three public health campaigns aimed at raising awareness among patients and caregivers regarding critical health issues. Since mid-2022, these campaigns have reached over half a million individuals, prompting significant engagement on topics such as pediatric COVID-19 vaccine safety, the risks of vaping, and high blood pressure control. The campaigns have demonstrated positive results, with increased likelihood of patients seeking information and discussing these health issues with their healthcare providers. The COVID-19 education initiative alone reached over 203,000 caregivers, with substantial interest in vaccination information.